

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Sep 29	The Philippines Inventory of Chemicals and Chemical Substances (PICCS) has been added to CHEMLIST
NEWS	3	Oct 27	New Extraction Code PAX now available in Derwent Files
NEWS	4	Oct 27	SET ABBREVIATIONS and SET PLURALS extended in Derwent World Patents Index files
NEWS	5	Oct 27	Patent Assignee Code Dictionary now available in Derwent Patent Files
NEWS	6	Oct 27	Plasdoc Key Serials Dictionary and Echoing added to Derwent Subscriber Files WPIDS and WPIX
NEWS	7	Nov 29	Derwent announces further increase in updates for DWPI
NEWS	8	Dec 5	French Multi-Disciplinary Database PASCAL Now on STN
NEWS	9	Dec 5	Trademarks on STN - New DEMAS and EUMAS Files
NEWS	10	Dec 15	2001 STN Pricing
NEWS	11	Dec 17	Merged CEABA-VTB for chemical engineering and biotechnology
NEWS	12	Dec 17	Corrosion Abstracts on STN
NEWS	13	Dec 17	SYNTHLINE from Prous Science now available on STN
NEWS	14	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS	15	Jan 05	AIDSLINE is being removed from STN
NEWS EXPRESS			FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:34:57 ON 15 JAN 2001

=> file biosis, dgene, hcaplus, uspat, japio, wpids, scisearch, embase, frosti, jicst, fsta, cen, ceaba, biotechds, biotechabs

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

TRY
0.60

SESSION
0.60

FILE 'BIOSIS' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'DGENE' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'HCAPLUS' ENTERED AT 09:37:01 ON 15 JAN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:37:01 ON 15 JAN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'WPIDS' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'SCISEARCH' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'EMBASE' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'FROSTI' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'JICST-EPLUS' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'FSTA' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'CEN' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CEABA-VTB' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (c) 2001 DECHEMA eV

FILE 'BIOTECHDS' ENTERED AT 09:37:01 ON 15 JAN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

=> s. prokaryotic elongation factor p

L1 2 PROKARYOTIC ELONGATION FACTOR P

=> d ll ti abs ibib tot

L1 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2001 ACS
TI Assays for modulators of elongation factor p activity
AB Disclosed are novel methods of using elongation factor p (efp) and
related
constituents of ribosomal complexes which comprise efp, the 50S ribosomal

subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compds. which modulate **prokaryotic elongation factor p** and modify cell function are described. Both in vitro and in vivo methods for identifying compds. which modulate such constituents and affect cell function are described. Such identified compds., including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compds., and antiseptics contg. such compds. are described. The present invention is also directed to methods and compds. that modulate **prokaryotic elongation factor p**.

ACCESSION NUMBER: 2000:535370 HCAPLUS
DOCUMENT NUMBER: 133:144893
TITLE: Assays for modulators of elongation factor p activity
INVENTOR(S): Poorman, Roger A.; Wells, Peter Andrew; Marotti, Keith
PATENT ASSIGNEE(S): R.; Shinabarger, Dean L.
SOURCE: Pharmacia and Upjohn, USA
PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045177	A1	20000803	WO 1999-US12073	19990528
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9942246	A1	20000818	AU 1999-42246	19990528
PRIORITY APPLN. INFO.:			US 1999-117473	19990127
			WO 1999-US12073	19990528

REFERENCE COUNT: 4
REFERENCE(S):
(1) Anon; 1998, 13, HCAPLUS
(2) Anon; 1999, 10, HCAPLUS
(3) Aoki, H; JOURNAL OF BIOLOGICAL CHEMISTRY 1997, V272(51), P32254 HCAPLUS
(4) Swaney, S; ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 1998, V42(12), P3251 HCAPLUS

L1 ANSWER 2 OF 2 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Identifying a compound which modulates the activity of **prokaryotic elongation factor p** (efp) for screening for compounds which can be used as antibiotics comprises contacting efp with
a compound and determining if efp activity is modified.
AN 2000-524303 [47] WPIDS
AB WO 200045177 A UPAB: 20000925
NOVELTY - A method (M1) for identifying a compound which modulates the activity of efp comprises contacting efp with a compound and determining whether the compound modifies activity of efp.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a method (M2) for identifying a compound which modulates efp activity comprising:

(a) contacting a cell containing efp with a compound identified by M1; and
 (b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates efp activity comprising:
 (a) contacting a composition comprising efp, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a compound; and
 (b) determining whether the compound allows fMet-tRNA to bind to a complex formed through the interaction of efp, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates efp activity comprising:
 (a) contacting efp with prokaryotic 30S subunit or 70S ribosome to form a composition;
 (b) contacting the composition with a compound; and
 (c) determining whether the compound binds to efp in association with the 30S subunit or 70S ribosome or interferes with the binding of efp and the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a compound which modulates efp activity comprising:
 (a) contacting efp with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;
 (b) contacting the second composition with the compound; and
 (c) determining whether the compound inhibits the first peptide bond reaction;

(5) a method (M6) for identifying a compound which modulates efp activity comprising:
 (a) contacting a cell or composition containing efp with a detectably labelled oxazolidinone compound known to bind efp;
 (b) contacting the composition or cell with an unlabelled compound; and
 (c) determining whether the unlabelled compound displaces the labelled oxazolidinone compound from the complex;

(6) a method (M7) for identifying a compound which modulates efp but not eukaryotic eIF5A activity comprising:
 (a) determining whether the compound modulates the activity of prokaryotic efp by M1 - M7;
 (b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;
 (c) contacting the second composition with a compound; and
 (d) determining whether the compound inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and
 (7) modulating the activity of prokaryotic efp, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the efp or cell or cell preparation containing the efp, the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an oxazolidinone compound.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS

DOC. NO. NON-CPI: N2000-387540
 DOC. NO. CPI: C2000-155724
 TITLE: Identifying a compound which modulates the activity of
prokaryotic elongation factor
p (efp) for screening for compounds which can be
 used as antibiotics comprises contacting efp with a
 compound and determining if efp activity is modified.
 B04 D16 S03
 DERWENT CLASS:
 INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A
 PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN
 COUNTRY COUNT: 86
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000045177	A1	20000803	(200047)*	EN	52
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB					
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU					
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR					
TT UA UG US UZ VN YU ZA ZW					
AU 9942246	A	20000818	(200057)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000045177	A1	WO 1999-US12073	19990528
AU 9942246	A	AU 1999-42246	19990528

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9942246	A Based on	WO 200045177

PRIORITY APPLN. INFO: US 1999-117473 19990127

=> d his

(FILE 'HOME' ENTERED AT 09:34:57 ON 15 JAN 2001)

FILE 'BIOSIS, DGENE, HCAPLUS, USPATFULL, JAPIO, WPIDS, SCISEARCH,
 EMBASE,
 FROSTI, JICST-EPLUS, FSTA, CEN, CEABA-VTB, BIOTECHDS' ENTERED AT
 09:37:01
 ON 15 JAN 2001

L1 2 S PROKARYOTIC ELONGATION FACTOR P

=> s enterococcus

L2 17 ENTEROCOCCUS

=> s enterococcus

L3 31746 ENTEROCOCCUS

=> s h influenzae

L4 13016 H INFLUENZAE

=> s s pneumoniae

L5 14202 S PNEUMONIAE

=> s s aureus

L6 49649 S AUREUS

=> s l3 and l4

L7 297 L3 AND L4

=> s l7 and l5

L8 134 L7 AND L5

=> s l8 and l6

L9 100 L8 AND L6

=> s l9 and method

L10 45 L9 AND METHOD

=> s intrinsic fluorescence

L11 5840 INTRINSIC FLUORESCENCE

=> d l1 and l11

L11 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:n

=> s l1 and l11

L12 1 L1 AND L11

=> d l12 ti abs ibib tot

L12 ANSWER 1 OF 1 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Identifying a compound which modulates the activity of **prokaryotic elongation factor p** (efp) for screening for compounds which can be used as antibiotics comprises contacting efp with
a compound and determining if efp activity is modified.
AN 2000-524303 [47] WPIDS
AB WO 200045177 A UPAB: 20000925
NOVELTY - A method (M1) for identifying a compound which modulates the activity of efp comprises contacting efp with a compound and determining whether the compound modifies activity of efp.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a method (M2) for identifying a compound which modulates efp activity comprising:
(a) contacting a cell containing efp with a compound identified by

M1; and

(b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates efp activity comprising:

(a) contacting a composition comprising efp, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a compound; and

(b) determining whether the compound allows fMet-tRNA to bind to a complex formed through the interaction of efp, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates efp activity comprising:

(a) contacting efp with prokaryotic 30S subunit or 70S ribosome to form a composition;

(b) contacting the composition with a compound; and

(c) determining whether the compound binds to efp in association

with

the 30S subunit or 70S ribosome or interferes with the binding of efp

and

the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a compound which modulates efp activity comprising:

(a) contacting efp with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;

(b) contacting the second composition with the compound; and

(c) determining whether the compound inhibits the first peptide bond reaction;

(5) a method (M6) for identifying a compound which modulates efp activity comprising:

(a) contacting a cell or composition containing efp with a detectably

labelled oxazolidinone compound known to bind efp;

(b) contacting the composition or cell with an unlabelled compound; and

(c) determining whether the unlabelled compound displaces the labelled oxazolidinone compound from the complex;

(6) a method (M7) for identifying a compound which modulates efp but not eukaryotic eIF5A activity comprising:

(a) determining whether the compound modulates the activity of prokaryotic efp by M1 - M7;

(b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;

(c) contacting the second composition with a compound; and

(d) determining whether the compound inhibits the first peptide bond reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and

(7) modulating the activity of prokaryotic efp, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the efp or

cell

or cell preparation containing the efp, the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an oxazolidinone compound.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS

DOC. NO. NON-CPI: N2000-387540

DOC. NO. CPI: C2000-155724
 TITLE: Identifying a compound which modulates the activity of
 prokaryotic elongation factor
 p (efp) for screening for compounds which can be
 used as antibiotics comprises contacting efp with a
 compound and determining if efp activity is modified.
 B04 D16 S03
 DERWENT CLASS:
 INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A
 PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN
 COUNTRY COUNT: 86
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000045177	A1	20000803	(200047)*	EN	52
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB					
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU					
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR					
TT UA UG US UZ VN YU ZA ZW					
AU 9942246	A	20000818	(200057)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000045177	A1	WO 1999-US12073	19990528
AU 9942246	A	AU 1999-42246	19990528

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9942246	A Based on	WO 200045177

PRIORITY APPLN. INFO: US 1999-117473 19990127

=> d his

(FILE 'HOME' ENTERED AT 09:34:57 ON 15 JAN 2001)

FILE 'BIOSIS, DGENE, HCAPLUS, USPATFULL, JAPIO, WPIDS, SCISEARCH,
 EMBASE,

FROSTI, JICST-EPLUS, FSTA, CEN, CEABA-VTB, BIOTECHDS' ENTERED AT
 09:37:01

ON 15 JAN 2001

L1 2 S PROKARYOTIC ELONGATION FACTOR P
 L2 17 S ENTEROCOCCUS
 L3 31746 S ENTEROCOCCUS
 L4 13016 S H INFLUENZAE
 L5 14202 S S PNEUMONIAE
 L6 49649 S S AUREUS
 L7 297 S L3 AND L4
 L8 134 S L7 AND L5
 L9 100 S L8 AND L6
 L10 45 S L9 AND METHOD
 L11 5840 S INTRINSIC FLUORESCENCE
 L12 1 S L1 AND L11

=> s oxazolidinone?

L13 9426 OXAZOINONE?

=> s l13 and l1

L14 2 L13 AND L1

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2001 ACS

TI Assays for modulators of elongation factor p activity

AB Disclosed are novel methods of using elongation factor p (efp) and related

constituents of ribosomal complexes which comprise efp, the 50S ribosomal subunit, the 30S ribosomal subunit, the 70S initiation complex, and related proteins, cofactors and enzymes. Methods of identifying compds. which modulate **prokaryotic elongation factor p** and modify cell function are described. Both in vitro and in vivo methods for identifying compds. which modulate such constituents and affect cell function are described. Such identified compds., including various antibiotics, which specifically affect cell growth, methods of treating various disorders with such compds., and antiseptics contg. such compds. are described. The present invention is also directed to methods and compds. that modulate **prokaryotic elongation factor p**.

ACCESSION NUMBER: 2000:535370 HCAPLUS

DOCUMENT NUMBER: 133:144893

TITLE: Assays for modulators of elongation factor p activity

INVENTOR(S): Poorman, Roger A.; Wells, Peter Andrew; Marotti, Keith

R.; Shinabarger, Dean L.

PATENT ASSIGNEE(S): Pharmacia and Upjohn, USA

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000045177	A1	20000803	WO 1999-US12073	19990528
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9942246	A1	20000818	AU 1999-42246	19990528
PRIORITY APPLN. INFO.:			US 1999-117473	19990127
			WO 1999-US12073	19990528

REFERENCE COUNT: 4

REFERENCE(S):

- (1) Anon; 1998, 13, HCAPLUS
- (2) Anon; 1999, 10, HCAPLUS
- (3) Aoki, H; JOURNAL OF BIOLOGICAL CHEMISTRY 1997, V272(51), P32254 HCAPLUS
- (4) Swaney, S; ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 1998, V42(12), P3251 HCAPLUS

TI Identifying a compound which modulates the activity of **prokaryotic elongation factor** (efp) for screening for compounds which can be used as antibiotics comprises contacting efp with

a compound and determining if efp activity is modified.

AN 2000-524303 [47] WPIDS

AB WO 200045177 A UPAB: 20000925

NOVELTY - A method (M1) for identifying a compound which modulates the activity of efp comprises contacting efp with a compound and determining whether the compound modifies activity of efp.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method (M2) for identifying a compound which modulates efp activity comprising:

(a) contacting a cell containing efp with a compound identified by M1; and

(b) determining whether the compound inhibits cell growth;

(2) a method (M3) for identifying a compound which modulates efp activity comprising:

(a) contacting a composition comprising efp, N-formylmethionyl-tRNA (fMet-tRNA), 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3 with a compound; and

(b) determining whether the compound allows fMet-tRNA to bind to a complex formed through the interaction of efp, 30S subunit, 50S, an mRNA containing an AUG sequence and initiation factors 1,2 and 3;

(3) a method (M4) for identifying a compound which modulates efp activity comprising:

(a) contacting efp with prokaryotic 30S subunit or 70S ribosome to form a composition;

(b) contacting the composition with a compound; and

(c) determining whether the compound binds to efp in association

with the 30S subunit or 70S ribosome or interferes with the binding of efp and the 30S subunit or 70S ribosome;

(4) a method (M5) for identifying a compound which modulates efp activity comprising:

(a) contacting efp with a composition comprising either 50S subunit or 70S ribosome, a tRNA fragment comprising CACCA-radiolabeled amino acid and a peptide bond donor to form a second composition;

(b) contacting the second composition with the compound; and

(c) determining whether the compound inhibits the first peptide bond reaction;

(5) a method (M6) for identifying a compound which modulates efp activity comprising:

(a) contacting a cell or composition containing efp with a

detectably labelled **oxazolidinone** compound known to bind efp;

(b) contacting the composition or cell with an unlabelled compound;

and (c) determining whether the unlabelled compound displaces the labelled **oxazolidinone** compound from the complex;

(6) a method (M7) for identifying a compound which modulates efp but not eukaryotic eIF5A activity comprising:

(a) determining whether the compound modulates the activity of prokaryotic efp by M1 - M7;

(b) contacting eIF5A with a composition comprising methionyl-tRNA (Met-tRNA), 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C, eIF-4D and a peptide bond donor to form a second composition;

(c) contacting the second composition with a compound; and

(d) determining whether the compound inhibits the first peptide bond

reaction of a complex formed through the interaction of eIF5A, Met-tRNA, 80S ribosome, an mRNA containing an AUG sequence, initiation factors eIF-2, eIF-3, eIF-5, eIF-4C and eIF-4D; and

(7) modulating the activity of prokaryotic efp, the 30S subunit, 50S subunit, 70S ribosome or L16 protein comprising contacting the efp or cell

or cell preparation containing the efp, the 30S subunit, 50S subunit, 70S ribosome or L16 protein with an **oxazolidinone** compound.

USE - To screen for compounds which modulate ribosome mediated peptide bond formation. These screening assays can be used to discover new and useful antibiotics.

ADVANTAGE - This screening method is more rapid and direct than currently available methods.

Dwg.0/0

ACCESSION NUMBER: 2000-524303 [47] WPIDS

DOC. NO. NON-CPI: N2000-387540

DOC. NO. CPI: C2000-155724

TITLE: Identifying a compound which modulates the activity of **prokaryotic elongation factor**

p (efp) for screening for compounds which can be used as antibiotics comprises contacting efp with a compound and determining if efp activity is modified.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): MAROTTI, K R; POORMAN, R A; SHINABARGER, D L; WELLS, P A

PATENT ASSIGNEE(S): (PHAA) PHARMACIA & UPJOHN

COUNTRY COUNT: 86

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000045177	A1	20000803	(200047)*	EN	52
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					
OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB					
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU					
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR					
TT UA UG US UZ VN YU ZA ZW					
AU 9942246	A	20000818	(200057)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000045177	A1	WO 1999-US12073	19990528
AU 9942246	A	AU 1999-42246	19990528

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9942246	A Based on	WO 200045177

PRIORITY APPLN. INFO: US 1999-117473 19990127

=> s efp?

L15 1227 EFP?

=> d his

(FILE 'HOME' ENTERED AT 09:34:57 ON 15 JAN 2001)

FILE 'BIOSIS, DGENE, HCAPLUS, USPATFULL, JAPIO, WIDS, SCISEARCH,
EMBASE,

FROSTI, JICST-EPLUS, FSTA, CEN, CEABA-VTB, BIOTECHDS' ENTERED AT
09:37:01

ON 15 JAN 2001

L1 2 S PROKARYOTIC ELONGATION FACTOR P
L2 17 S ENTEROCCUS
L3 31746 S ENTEROCOCCUS
L4 13016 S H INFLUENZAE
L5 14202 S S PNEUMONIAE
L6 49649 S S AUREUS
L7 297 S L3 AND L4
L8 134 S L7 AND L5
L9 100 S L8 AND L6
L10 45 S L9 AND METHOD
L11 5840 S INTRINSIC FLUORESCENCE
L12 1 S L1 AND L11
L13 9426 S OXAZOLIDINONE?
L14 2 S L13 AND L1
L15 1227 S EFP?

=> s l15 and l13

L16 2 L15 AND L13